{"id":"NCT02115750","sponsor":"Coherus Biosciences, Inc.","briefTitle":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)","officialTitle":"A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-10","completion":"2016-05","firstPosted":"2014-04-16","resultsPosted":"2019-06-26","lastUpdate":"2019-06-26"},"enrollment":647,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Etanercept","otherNames":["Enbrel","European Enbrel"]},{"type":"DRUG","name":"CHS-0214","otherNames":[]}],"arms":[{"label":"Enbrel (etanercept)","type":"ACTIVE_COMPARATOR"},{"label":"CHS-0214","type":"EXPERIMENTAL"}],"summary":"This is a two part study comparing CHS-0214 to Enbrel in patients with active rheumatoid arthritis and an inadequate response with Methotrexate (MTX) who are naive to biologic therapies.\n\nPt.1 is a 24-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 20% improvement in American College of Rheumatology criteria (ACR-20) at week 24. Comparing CHS-0214 to Enbrel for efficacy and safety.\n\nPt. 2 is an open-label single arm study in which patients with at least an ACR-20 response receive CHS-0214. Continued response and safety will be evaluated.","primaryOutcome":{"measure":"ACR-20 - 20% Improvement According to American College of Rheumatology Criteria","timeFrame":"24-weeks","effectByArm":[{"arm":"Enbrel (Etanercept)","deltaMin":232,"sd":null},{"arm":"CHS-0214","deltaMin":233,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":141,"countries":["United States","Belarus","France","Germany","Hungary","Israel","Japan","Poland","Russia","South Africa","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":320},"commonTop":["Nasopharyngitis","Injury, poisoning and procedural complications","injection Site Reaction","Upper Respiratory Tract Infection","Urinary Tract Infection"]}}